Visual Evoked Potential Testing for Glaucoma

This policy addresses visual evoked potential (VEP) testing—including steady‑state, pattern, multifocal, and isolated‑check (icVEP) modalities and FDA‑cleared systems like Diopsys NOVA—for evaluation of glaucoma or visual pathway function in patients with suspected or confirmed open‑angle, angle‑closure, or normal‑tension glaucoma, in at‑risk individuals (eg, elevated IOP, family history, high myopia) and in infants, children, or non‑cooperative adults. However, VEP testing for glaucoma is considered experimental/investigational and not covered because evidence is limited and inconsistent (small, cross‑sectional studies, no clear superiority over standard automated perimetry), and test validity is affected by device/software versions, noise, and administration factors pending further research.

"Open-angle glaucoma — chronic, typically painless progressive peripheral vision loss that may progress to central vision loss if untreated."